Oncotarget

Research Papers:

Serum N-glycome alterations in colorectal cancer associate with survival

Stefan W. de Vroome, Stephanie Holst _, Mar Rodriguez Girondo, Yuri E.M. van der Burgt, Wilma E. Mesker, Rob A.E.M. Tollenaar and Manfred Wuhrer

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:30610-30623. https://doi.org/10.18632/oncotarget.25753

Metrics: PDF 531 views  |   HTML 1254 views  |   ?  


Abstract

Stefan W. de Vroome1,*, Stephanie Holst2,*, Mar Rodriguez Girondo3, Yuri E.M. van der Burgt2, Wilma E. Mesker1, Rob A.E.M. Tollenaar1 and Manfred Wuhrer2

1Department of Surgery, Leiden University Medical Center, 2300 RC Leiden, The Netherlands

2Center for Proteomics and Metabolomics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands

3Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, 2300 RC Leiden, The Netherlands

*These authors contributed equally to this work

Correspondence to:

Stephanie Holst, email: s.holst@lumc.nl

Keywords: N-glycans; colorectal cancer; serum biomarker panel; prognosis, survival

Received: May 30, 2018     Accepted: June 25, 2018     Published: July 17, 2018

ABSTRACT

Proteins are routinely measured in clinical laboratories for diagnosis, prognosis and therapy monitoring. Nevertheless, both test improvements (performance) and innovations (biomarkers) are needed, and protein N-glycosylation offers a rich source of potential markers. Here, we have analyzed the total serum N-glycome in a matched case-control study (124 cases versus 124 controls) of colorectal cancer patients. The results were validated in an independent sample cohort (both 61 cases versus 61 controls) and further tested in post-operative samples of cured patients. Our results revealed significant differences between patients and controls, with increased size (antennae) and sialylation of the N-glycans in the colorectal cancer patient sera as compared to mainly di-antennary N-glycans in sera from controls. Furthermore, glycan alterations showed strong associations with cancer stage and survival: The five-year survival rate largely varied between patients with an altered serum N-glycome (46%) and an N-glycome similar to controls (87%). Importantly, the total serum N-glycome showed prognostic value beyond age and stage. This clinical glycomics study provides novel serum biomarker candidates and shows the potential of total serum N-glycans as a prognostic panel. Moreover, serum N-glycome changes reverted to a control-like profile after successful treatment as was demonstrated from pre- and post-operative samples.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25753